NASDAQ$DSGN
Design Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported second quarter 2022 financial results and highlighted upcoming milestones.
Design Therapeutics reported a net loss of $15.0 million for the second quarter of 2022 and holds a strong financial position with $359.4 million in cash and securities. The company is advancing its pipeline, with initial data from the Friedreich Ataxia Phase 1 trial expected in the fourth quarter of 2022.
- Initial data from the Friedreich Ataxia Phase 1 trial of DT-216 is expected in the fourth quarter of 2022.
- The company's GeneTAC™ program for myotonic dystrophy type-1 (DM1) has advanced.
- Compelling preclinical data was announced in Fuchs endothelial corneal dystrophy (FECD).
- Cash, cash equivalents and marketable securities were $359.4 million as of June 30, 2022, supporting a multi-year operating runway.
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Design Therapeutics anticipates several milestones, including initial data from the DT-216 Phase 1 trial, clinical development for the DM1 program, and advancing research in FECD.
Tailwinds
- Initial data from the single-ascending dose portion of the Phase 1 trial for DT-216 is expected in the fourth quarter of 2022.
- Clinical development for the DM1 program is anticipated in 2023.
- Research in FECD is advancing throughout the second half of 2022.
- Design's approach paves the way for disease-modifying treatments for patients with inherited genetic diseases.
- The company is bringing forward a new class of treatments for patients living with devastating genetic diseases.
Headwinds
- Clinical trial and patient enrollment are affected by many factors.
- Difficulties or delays encountered with clinical trials may adversely affect Design’s ongoing Phase 1 clinical trial for DT-216.
- Promising early research or clinical trials may not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
- Changes in Design’s plans to develop its product candidates.
- Reliance on third parties to successfully conduct clinical trials and preclinical studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro